Associated Genetic Biomarkers
Phophoinositide-3-kinase, regulatory subunit 3 (gamma) (PIK3R3) is a gene that encodes a protein that functions in the regulation of phosphatidylinositol 3-kinase activity. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
PIK3R3 is altered in 0.57% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, prostate adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in PIK3R3 are PIK3R3 Mutation (0.31%), PIK3R3 Amplification (0.04%), PIK3R3 M295* (0.02%), PIK3R3 Loss (0.01%), and PIK3R3 A449T (0.01%) .
PIK3R3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PIK3R3 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with PIK3R3 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is PIK3R3 Mutation .
Paxalisib and radiation therapy are the most frequent therapies in trials with PIK3R3 as an inclusion criteria .
Significance of PIK3R3 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.